cpi-1205
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2015 (NCT02395601)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
EZH2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCN(CC(F)(F)F)CC2)c2ccccc12- Mol. weight
- 518.58 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297463 ↗
Also known as
- cpi-1205
- cpi-1205
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03525795 | Phase 1/Phase 2 (Phase 2) | Dec 14, 2017 | Constellation Pharmaceuticals |
| NCT03480646 | Phase 1/Phase 2 (Phase 2) | Nov 15, 2017 | Constellation Pharmaceuticals |
| NCT02395601 | Phase 1 | Mar 1, 2015 | Constellation Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Constellation Pharmaceuticals | For profit | 3 | 3 | 2 | 2015 |
1 organizations
Page 1 / 1